Ebola Virus Disease (EVD) is a Category A pathogen and is considered to be a "threat for individuals as well as public health." The Ebola virus disease pandemic has been proclaimed by the WHO as a global public health emergency. The fast spread of Ebola in West Africa demonstrates that the fatal disease can present a grave danger to human safety.
The scenario in Guinea, Liberia and Sierra Lion continue worrisome as the number of fresh instances reported continues to rise quickly. Whilst West Africa is the epicenter of the current Ebola crisis, recent finding show that Ebola virus has also spread its tentacles beyond it as well.
For more than a century, the US Government has been investing sustainably in R&D related to biodefense to generate anti-Ebola MCMs.
Funding for a majority of countermeasures in the pipeline has been developed by investing in the National Institute of Allergy and Infectant Diseases (NIAID) through the Biodefense and Emerging Infectious Diseases Program.
The pharmaceutical companies have great possibilities to explore, because of their elevated mortality rate and the lack of effective therapies against Ebola. The leading businesses that focus on study operations to create effective ebola virus disease medicines include Tekmira Pharmaceuticals, Bio Cryst Pharmaceutical Inc., Serepata Therapeutics, NewLink Genetics and Mapp Biopharmaceutical.
To get detailed information on Ebola Treatment market report click on Read Full Report
On a much larger scale, the global market size of biodefense was estimated at $5.47 billion in 2018 and is projected to grow over the forecast period by 4.5 per cent at the CAGR. A key driver of the market is increased government initiatives to enhance preparedness for chemical, biological, nuclear, and radiological (CBRN) threats. More technology such as forensic pathogen detection gene chips, nanotechnology, database management systems and advanced biodefense hardware are projected to drive the market further.
The insight to global biodefence market can be viewed Read Full Report